|Microcurrent stimulation (MCS) is a form of electrical acupuncture.|
Some alternative eye professionals and acupuncturists use this to treat macular degeneration or to slow its progress.
It involves the administration of very precise amounts of tightly controlled electrical current through electrodes applied to the skin at specific areas around the eye.
A small battery-operated device delivers low-intensity electricity to points around the eyes.
This stimulation is thought to increase the blood flow to the eyes and as a result the eye is
more oxygen gets to the tissues, and
waste products are more efficiently removed.
It is also believed that MCS helps to stimulate retinal cells that have become somewhat dormant and sluggish.
The procedure is
No side effects or adverse reactions have been observed.
No increase in the conversion to the wet form of ARMD has been seen in those who have been treated.
In a consensus statement by the NIH reports that, "One of the advantages...is that the incidence of adverse affects is substantially lower than that of many drugs or other accepted medical procedures used for the same conditions."
In respect to the legal status of MCS Therapy, the Food and Drug Administration regulates the sale of medical devices. Before a medical device can be legally sold or used in the U.S., the person or company that wants to sell or use the device must seek approval from the FDA.
To gain approval, they must present evidence that the device is reasonably safe and effective for a particular use. The devices used in MCS therapy were originally developed and approved for the relief of chronic, untreatable pain.
Once the FDA has approved a medical device, a doctor may decide to use that device for other indications if the doctor feels it is in the best interest of a patient.
Subsequently, when an approved device is used for anything other than its FDA approved indication, it is called off-label.
MCS therapy for the treatment of retinal disease is considered an off-label use.
The Macular Degeneration Foundation's two-year preliminary MCS trial involving 120 patients resulted in an average of:
* 68% improvement over pre-treatment vision for patients with the dry macular degeneration. * 58% improvement over pre-treatment vision for those with the wet form of macular degeneration. * Among certain subsets of patients with dry disease the results were even more dramatic, with a third gaining 100 percent or more improvement and a sixth gaining 150 percent or more improvement.
Patients were able to sustain these vision improvements over time by periodic self-administration of booster treatments and many report that this therapy has made a remarkable difference to their lives.
To read more specifics from MD Support go to:
If you want to know more about microcurrent stimulation please contact Dr. Marc Grossman, a licensed optometrist and acupuncturist. Marc is an international lecturer on natural eye care, author of four books on vision and natural eye care, and practitioner since 1980. Contact Natural Eye Care by clicking here:
The data presented here has not been reviewed by the FDA, nor has it been peer reviewed. The microcurrent devices used are approved by the FDA for the treatment of pain, but they have not been approved for other uses. The use of a device for an off-label use by a physician is legal. The use of microcurrent stimulation discussed here is only one part of a comprehensive program for supporting visual health, and should not replace any treatment prescribed by your physician.
Would you like to be updated on the latest:
√ Clinical Trials?
√ Prevention of Macular Degeneration?
√ Tips for Daily Living?
√ Food Suggestions for a Macular Degeneration Diet?
√ Ideas on Visual Aids to Maximize your Sight?
If you said "yes" to any of the above, sign up for my monthly Macular Degeneration News.